VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/34293038/

⇱ Both high and low pre-infection glucose levels associated with increased risk for severe COVID-19: New insights from a population-based study - PubMed


Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

Importance: Patients with diabetes are known to be at increased risk for infections including severe coronavirus disease 2019 (COVID-19) but the relationship between COVID-19 severity and specific pre-infection glucose levels is not known.

Objective: To assess the differential effects of pre-infection glucose levels on the risk for severe COVID-19 amongst patients with and without diabetes.

Design: Population based historical cohort study.

Setting: National state-mandated HMO.

Patients: All adult patients with a positive SARS-COV2 test between March-October 2020.

Exposure: Recent fasting blood glucose (FBG) and glycated hemoglobin (HBA1C), age, gender, body mass index (BMI) and diagnoses of diabetes, hypertension, ischemic heart disease.

Outcome: Risk for severe COVID-19, defined as resulting in ≥10 hospitalization days, ICU admission or death.

Results: 37,121 patients with a positive SARS-COV2 test were identified; 707 defined as severe (1.9%). Unadjusted risk factors for severe disease were age (OR = 1.1 for every year increase; 95% CI 1.09-1.11, p < 0.001), male gender (OR = 1.34, 95% CI 1.06-1.68, p = 0.012); BMI (OR = 1.02 for 1 kg/m2 increase, 95% CI 1.00-1.04, p = 0.025). Controlling for these factors, we found an association between pre-infection FBG and the risk of severe COVID-19, with a differential effect in patients with and without a diagnosis of diabetes. For patients without diabetes, elevated FBG in the pre-diabetes range (106-125 mg/dl) was associated with severe COVID-19 (OR 1.55 95% CI 1.04-2.26 p = 0.027). For patients with a diagnosis of diabetes, we found a J-shaped association between pre-infection glucose control and the risk for severe COVID-19 where the lowest risk for was for patients with FBG 106-125 mg/dl; the risk increased with higher pre-infection glucose levels but strikingly also for patients with a low pre-infection FBG (<100mg/dl) or HbA1C (<5.7%).

Conclusions and relevance: Elevated pre-infection blood glucose is a risk factor for severe COVID-19 even in non-diabetics. For patients with a diagnosis of diabetes both high as well as low pre-infection glucose levels are risk factors for severe COVID-19. Further research is required to assess whether these associations are causal, but we believe these findings can already have clinical implications for COVID-19 risk assessment and stratification.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

👁 Fig 1
Fig 1
Left (A): Percentage of severe COVID-19 (death/ICU/≥10 hospitalization days) given prior fasting glucose range (mg/dl), for patients with no diagnosis of diabetes vs. patients with a diagnosis of diabetes. The numbers on the bars represent the number of patients in each sub-category, whereas the inner partition into red and blue represents the conditional distribution of severity, given the patients are in the specific range of FBG. Right (B): Percentage of severe COVID-19 (death/ICU/≥10 hospitalization days) given prior HbA1C, for patients with no diagnosis of diabetes (left) vs. patients with a diagnosis of diabetes (right).
👁 Fig 2
Fig 2. Frequency of severe COVID-19 (death/ICU/ hospitalization ≥10 days) by pre-infection fasting blood glucose, among patients with (in black) and without (in grey) a diagnosis of diabetes.

References

    1. Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of Infection in Type and Type 2 Diabetes Compared with the General Population: A Matched Cohort Study. Diabetes Care. 2018;3:513–521. doi: 10.2337/dc17-2131 - DOI - PubMed
    1. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The Lancet Diabetes & Endocrinology. 2020;8:823. doi: 10.1016/S2213-8587(20)30271-0 - DOI - PMC - PubMed
    1. Katulanda P, Dissanayake HA, Ranathunga I, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia. 2020;63:1440. doi: 10.1007/s00125-020-05164-x - DOI - PMC - PubMed
    1. Merzon E, Green IS, et al. Haemoglobin A1c is a predictor of COVID?19 severity in patients with diabetes. Diabetes/metabolism research and reviews. 2020;3398 doi: 10.1002/dmrr.3398 - DOI - PMC - PubMed
    1. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. COVID-19 in critically ill patients in the Seattle region—case series. New England Journal of Medicine. 2020;382(21):2012–2022. doi: 10.1056/NEJMoa2004500 - DOI - PMC - PubMed
Cite

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.